| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8443866 | European Journal of Cancer | 2013 | 7 Pages |
Abstract
The use of the 70-gene signature, as judged appropriate by doctors and patients and supported by a low risk 70-gene signature as an oncological safe choice, was also found to be cost-effective.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
V.P. Retèl, M.A. Joore, C.A. Drukker, J.M. Bueno-de-Mesquita, M. Knauer, H. van Tinteren, S.C. Linn, W.H. van Harten,